High Risk Prostate Cancer Prevention Study
Over 180,000 new cases of prostate cancer are diagnosed in the United States each year,
making prostate cancer the most frequently diagnosed cancer in men. With an estimated
28,660 deaths occurring in 2008, prostate cancer is the second leading cause of cancer death
in men. In Kansas, prostate cancer is also the most frequent cancer among men and ranked
third (253 deaths in 2006) behind lung cancer (884 deaths in 2006) and colorectal cancer
(273 deaths in 2006) in cancer related mortality. Despite the significant morbidity and
mortality related to this disease, screening and treatment approaches remain controversial
and there is significant morbidity related to the treatment of early stage disease.
Preventative strategies and strategies which identify patients at highest risk are needed
desperately.
The goal of this proposal is to study the molecular effects of the chemopreventative agent,
finasteride in combination with dietary soy supplementation in patients at high risk for the
development prostate cancer.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Biomarkers will be identified to help predict future prostate cancer risks and patients likely to benefit from preventive strategies
2 years from completion of enrollment
Yes
Peter J Van Veldhuizen, MD
Principal Investigator
University of Kansas
United States: Food and Drug Administration
12052
NCT01174953
July 2010
September 2014
Name | Location |
---|---|
University of Kansas Medical Center | Kansas City, Kansas 66160-7353 |
Veterans Administration Medical Centenr | Kansas City, Missouri 64128 |